Lyell Immunopharma is presenting nonclinical data at SITC on LYL119

Lyell Immunopharma is presenting new nonclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, SITC, on innovations designed to shorten tumor infiltrating lymphocyte manufacturing, LYL119, its second generation ROR1-targeted CAR T cell product candidate, as well as data on new technologies and the design of its two clinical trials in progress. “We remain confident that generating T cells with the ability to resist exhaustion and qualities of durable stemness will unlock the potential of effective cell therapy for solid tumors, and our SITC presentations highlight the progress we are making across our robust pipeline of product candidates and platform technologies designed to achieve this,” said Gary Lee, Ph.D., chief scientific officer at Lyell. “We also highlight new data on our Epi-R P2 manufacturing process, a manufacturing innovation designed to enable faster delivery of TIL product to patients without sacrificing the desired yield, stemness phenotype and retention of tumor reactive clones.” Four presentations highlight new nonclinical data from Lyell’s product pipeline and research programs, including: Lyell’s novel Epi-R(TM) P2 manufacturing protocol to shorten delivery time of TIL product to patients; New nonclinical data on LYL119, Lyell’s second-generation ROR1-targeted CAR T-cell therapy; A new technology being advanced through a collaboration between Lyell and Outpace to enable tumor-restricted IL-12 activity to enhance solid tumor T cell therapies; Lyell’s rejuvenation technology which has shown the potential to “turn back” the epigenetic clock to generate more stem-like T cells with reduced epigenetic age and enhanced proliferation ability. Two additional presentations highlight the design of Lyell’s two ongoing Phase 1 clinical trials in progress.